ArticleCancer research2009
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.BMC veterinary research · 2015Trial
- FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy.Cancer cell international · 2026Review
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation.Hematology, transfusion and cell therapy · 2021Article
- Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins.Cancer research · 2021Article
- Intra- and Extracellular Effector Vesicles From Human T And NK Cells: Same-Same, but Different?Frontiers in immunology · 2021Review
- Stress Management: Death Receptor Signalling and Cross-Talks with the Unfolded Protein Response in Cancer.Cancers · 2020Review
- TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity.Cancers · 2019Review
- T Cells and Regulated Cell Death: Kill or Be Killed.International review of cell and molecular biology · 2019Review
- Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.Cancer science · 2017Article
- Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Cancer research · 2015Article
- Challenges and future perspectives of T cell immunotherapy in cancer.Immunology letters · 2015Review
- Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.Advances in cancer research · 2015Review
- WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.Cancer research · 2014Article
- Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.Nature medicine · 2014Article
- Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands.Cancer biology & therapy · 2013Article
- Fas expression by tumor stroma is required for cancer eradication.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression.The Journal of biological chemistry · 2012Article
- Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.PloS one · 2012Article
- Mechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responses.PloS one · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
The biological relevance of the perforin and Fas ligand (FasL) cytolytic pathways of CD8(+) T lymphocytes (CTL) for cancer immunotherapy is controversial. We investigated the importance of these pathways in a murine renal cell carcinoma expressing influenza viral hemagglutinin as a defined surrogate antigen (Renca-HA). Following Renca-HA injection, all FasL-dysfunctional FasL(gld/gld) mice (n = 54) died from Renca-HA tumors by day 62. By contrast, perforin(-/-) (51%; n = 45) and Fas(lpr/lpr) (55%; n = 51) mice remained tumor-free at day 360. Blocking FasL in vivo inhibited tumor rejection in these mice. Moreover, established Renca-HA tumors were cleared more efficiently by adoptively transferred HA(518-526)-specific T-cell receptor-transgenic CTL using FasL rather than perforin. Strikingly, a range of mouse tumor cells presenting low concentrations of immunogenic peptide were all preferentially lysed by the FasL but not the Pfp-mediated effector pathway of CTL, whereas at higher peptide concentrations, the preference in effector pathway usage by CTL was lost. Interestingly, a number of human renal cancer lines were also susceptible to FasL-mediated cytotoxicity. Therefore, the FasL cytolytic pathway may be particularly important for eradicating Fas-sensitive tumors presenting low levels of MHC class I-associated antigens following adoptive T-cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.